tiprankstipranks
Trending News
More News >
Kaken Pharmaceutical Co Ltd (KKPCF)
OTHER OTC:KKPCF

Kaken Pharmaceutical Co (KKPCF) Price & Analysis

Compare
4 Followers

KKPCF Stock Chart & Stats

$23.65
-$2.42(-8.28%)
At close: 4:00 PM EST
$23.65
-$2.42(-8.28%)

Bulls Say, Bears Say

Bulls Say
Very Low LeverageExtremely low debt (D/E 0.025) and an 80% equity ratio provide durable financial flexibility. This reduces refinancing and solvency risk, lets management fund R&D, partnerships or M&A internally, and cushions the firm against cyclical or regulatory shocks over the medium term.
High And Resilient MarginsStrong gross and operating margins reflect a branded specialty product mix and efficient cost structure. High margins support sustained reinvestment in development and commercialization, allowing the company to maintain profitability even if top-line growth slows in the coming months.
Solid Cash GenerationOperating cash flow exceeding net income (OCF/NI 2.14) and recent free cash flow growth indicate healthy cash conversion. Reliable cash generation funds clinical programs, licensing deals, dividends or capex without heavy external financing, strengthening strategic optionality.
Bears Say
Recent Revenue DeclineA near-19% reported revenue decline signals meaningful top-line weakness that can persist absent new product wins or market expansion. Sustained revenue contraction would pressure margins, cash flow predictability, and the company's ability to finance R&D and commercialization over the medium term.
Severe EPS ContractionEPS contraction over 100% indicates a sharp earnings hit that could stem from lower sales, one-time charges, or margin compression. Such swings reduce retained earnings and increase uncertainty over dividend capacity and reinvestment, undermining long-term earnings stability.
Domestic Concentration & NHI ExposureHeavy reliance on Japanese branded sales and the NHI pricing system creates structural regulatory and pricing risk. Periodic NHI price revisions can materially change realized prices and revenue, limiting pricing power and making growth dependent on geographic or portfolio diversification.

KKPCF FAQ

What was Kaken Pharmaceutical Co Ltd’s price range in the past 12 months?
Kaken Pharmaceutical Co Ltd lowest stock price was $20.68 and its highest was $35.09 in the past 12 months.
    What is Kaken Pharmaceutical Co Ltd’s market cap?
    Kaken Pharmaceutical Co Ltd’s market cap is $973.49M.
      When is Kaken Pharmaceutical Co Ltd’s upcoming earnings report date?
      Kaken Pharmaceutical Co Ltd’s upcoming earnings report date is May 13, 2026 which is in 67 days.
        How were Kaken Pharmaceutical Co Ltd’s earnings last quarter?
        Kaken Pharmaceutical Co Ltd released its earnings results on Feb 06, 2026. The company reported $0.068 earnings per share for the quarter, missing the consensus estimate of $0.157 by -$0.089.
          Is Kaken Pharmaceutical Co Ltd overvalued?
          According to Wall Street analysts Kaken Pharmaceutical Co Ltd’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does Kaken Pharmaceutical Co Ltd pay dividends?
            Kaken Pharmaceutical Co Ltd pays a Semiannually dividend of $0.605 which represents an annual dividend yield of 4.34%. See more information on Kaken Pharmaceutical Co Ltd dividends here
              What is Kaken Pharmaceutical Co Ltd’s EPS estimate?
              Kaken Pharmaceutical Co Ltd’s EPS estimate is 0.3.
                How many shares outstanding does Kaken Pharmaceutical Co Ltd have?
                Kaken Pharmaceutical Co Ltd has 44,139,730 shares outstanding.
                  What happened to Kaken Pharmaceutical Co Ltd’s price movement after its last earnings report?
                  Kaken Pharmaceutical Co Ltd reported an EPS of $0.068 in its last earnings report, missing expectations of $0.157. Following the earnings report the stock price went down -0.149%.
                    Which hedge fund is a major shareholder of Kaken Pharmaceutical Co Ltd?
                    Currently, no hedge funds are holding shares in KKPCF
                    What is the TipRanks Smart Score and how is it calculated?
                    Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

                      Company Description

                      Kaken Pharmaceutical Co Ltd

                      Kaken Pharmaceutical Co., Ltd. produces, markets, and sells medical products, medical devices, and agrochemicals in Japan and internationally. It offers pharmaceutical products and medical devices, such as Clenafin, a topical treatment for onychomycosis; Artz, an anti-osteoarthritis agent; Seprafilm, a semitransparent film-type absorbable adhesion barrier, which is applied to damaged tissue; Fiblast, a spray-on drug for the treatment of pressure ulcers and other skin ulcers; Regroth, a medicinal product for periodontal regeneration; and Hernicore for the treatment of lumbar disc herniation. The company also provides Adofeed, a pain- and inflammation-relieving plaster; Ebrantil for the treatment of dysuria and hypertension; Procylin, an oral-use prostaglandin I2 analog; Lipidil, an anti-hyperlipidemia agent; Mentax, an anti-trichophyton agent; and Loxoprofen Na Tape, a pain-relieving and anti-inflammatory plaster. In addition, it offers Ropion, a pain relief injection; and agrochemicals and animal health products, including Polyoxins that is used as fungicide; Pentoxazone, a rice herbicide; and Salinomycin, an anti-coccidial feed additive for chicken. Further, the company is developing BBI-4000 that has completed phase III clinical trial for primary axillary hyperhidrosis; KMW-1, which is in phase III clinical trial for the removal of eschar with thermal burns; KAR for treatment of hide lice infestation; and KP-607, which is in phase II clinical trial for the treatment of onychomycosis. Additionally, it is involved in the rental of Bunkyo Green Court, a commercial complex. The company offers its products under the Mentax Lotrimin Ultra, Mentax Butena, Mentax, Kaifen, Fiblast, and Jublia brands. It has license agreements with Corbus Pharmaceuticals Holdings, Inc. and Arbor Pharmaceuticals, LLC. Kaken Pharmaceutical Co., Ltd. was founded in 1917 and is headquartered in Tokyo, Japan.

                      Kaken Pharmaceutical Co (KKPCF) Earnings & Revenues

                      Similar Stocks
                      Company
                      Price & Change
                      Follow
                      Kissei Pharmaceutical Co
                      Towa Pharmaceutical Co
                      Mochida Pharmaceutical Co., Ltd.
                      KYORIN Pharmaceutical Co.,Ltd.
                      SAWAI GROUP HOLDINGS Co., Ltd.

                      Ownership Overview

                      3.77%93.62%
                      Insiders
                      ― Other Institutional Investors
                      93.62% Public Companies and
                      Individual Investors

                      Options Prices

                      Currently, No data available
                      ---
                      Popular Stocks